

PRESS RELEASE – FOR IMMEDIATE RELEASE

IntegraGen Reports Revenue for First Half of 2015

Growth of 1% with high level of orders booked during first half of year

- **Revenue of € 2.6 million, up 1% from the first half of 2014**
- **Very strong growth in order intake (+25%)**
- **Numerous scientific and commercial advances announced in the first half**

EVRY, France (July 9, 2015) - IntegraGen (FR0010908723 - ALINT - Eligible for PEA-SME), a leading expert in decoding the genome and specializing in the development and commercialization of molecular diagnostic tests, today announced its sales for the first half 2015.

Revenue growth of Genomic Services in the first half and strong increase in order intake.

Sales for IntegraGen's business totaled € 2.6 million as of June 30, 2015, up 1% compared to the first half of 2014. Sales growth was limited by the amount of samples received in the first quarter of 2015 with the pace of growth increasing during the second quarter. This seasonal effect masked the substantial growth in new projects the company experienced with order intake during the first half of 2015 increasing by over 25% compared to the same period in 2014. This increase suggests a strong performance for the second half of 2015. The increase in genomic services projects was supported by the increased activity of the clinical genomics platform at Gustave Roussy, which is now operating and accepting samples for several hospitals, and the launch of microbial sequencing activity at the Pasteur Institute, whose launch was announced in April. A partnership with HEGP (Georges Pompidou European Hospital) announced this week is also expected to impact genomics services growth in the coming months.

Finally, the launch of GeCo (Genomic Consulting), the expert service in bioinformatics and biostatistics the company introduced in the second quarter of 2015, has already attracted more customers and it is anticipated this service will aid revenue growth throughout the remainder of the year.

Promising scientific findings associated with oncology diagnostics activity

Since January, the company has presented significant technical and scientific research results at several meetings. This includes data from studies conducted as a result of several partnerships the company has established with research teams. Data from the New EPOC and PICCOLO studies confirm the important role the hsa-miR-31-3p biomarker has in personalizing the therapeutic management of colon cancer. These results were recently presented at the 2015 Annual ACSO meeting in Chicago. Furthermore, data presented at the ELCC in Geneva showed for the first time an association between the expression of the hsa-miR-31-3p biomarker and effects on survival of treatment of some forms of lung cancer, paving the way for a new applications of the biomarker.

The U.S. activity in autism remains marginal as the company explores the identification of licensing partner who could effectively drive the commercialization of the test ARISk® Test in this market.

Commenting on the announcement of the revenue results for the 1st half 2015, Courtieu Bernard, CEO of the company said: "IntegraGen has realized strong commercial, operational and scientific results in the first half 2015. These results illustrate the quality of our offerings and our ability to develop projects tailored to our clients' and medical & scientific community expectations along with the effectiveness of our strategy of differentiation in onco-genomics."

IntegraGen will publish its interim results October 6, 2015.

ABOUT INTEGRAGEN

IntegraGen is a company that specializes in deciphering the human genome and produces relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients.

As of December 31, 2014, IntegraGen had 34 employees and generated revenue of €6 million during 2014. Based in the Evry Genopole, IntegraGen also has an office in the U.S. located in Cambridge, Massachusetts.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - Eligible for PEA-SME)

For more information on IntegraGen visit www.integragen.com.



CONTACTS

INTEGRAGEN

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel. : +33 (0)1 60 91 09 00

NEWCAP

Investor and Media Relations

Emmanuel HUYNH
Louis-Victor DELOUVRIER
Nicolas MERIGEAU
integragen@newcap.fr
Tel. : +33 (0)1 44 71 94 94